Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 January 2018

Indication(s)

Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/004312
Orphan designation Yes
Date First Approved 30-05-2017
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Biogen Idec Ltd